Analysts forecast that Rubius Therapeutics, Inc. (NASDAQ:RUBY) will report earnings per share (EPS) of ($0.55) for the current quarter, Zacks reports. Zero analysts have issued estimates for Rubius Therapeutics’ earnings, with estimates ranging from ($0.59) to ($0.51). Rubius Therapeutics reported earnings per share of ($0.51) in the same quarter last year, which would suggest a negative year-over-year growth rate of 7.8%. The company is scheduled to issue its next earnings results on Monday, November 8th.
On average, analysts expect that Rubius Therapeutics will report full year earnings of ($2.17) per share for the current year, with EPS estimates ranging from ($2.29) to ($2.06). For the next financial year, analysts forecast that the company will report earnings of ($2.27) per share, with EPS estimates ranging from ($2.59) to ($2.07). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Rubius Therapeutics.
Rubius Therapeutics (NASDAQ:RUBY) last posted its quarterly earnings results on Monday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.08).
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its stake in shares of Rubius Therapeutics by 5.4% in the second quarter. Arizona State Retirement System now owns 9,930 shares of the company’s stock worth $242,000 after acquiring an additional 507 shares during the period. Virtus ETF Advisers LLC boosted its position in shares of Rubius Therapeutics by 1.8% in the 1st quarter. Virtus ETF Advisers LLC now owns 34,396 shares of the company’s stock worth $911,000 after purchasing an additional 603 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Rubius Therapeutics by 25.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,535 shares of the company’s stock worth $86,000 after acquiring an additional 724 shares during the period. Legal & General Group Plc increased its stake in Rubius Therapeutics by 34.3% during the 2nd quarter. Legal & General Group Plc now owns 6,376 shares of the company’s stock worth $155,000 after buying an additional 1,629 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Rubius Therapeutics by 13.1% during the 2nd quarter. Squarepoint Ops LLC now owns 17,500 shares of the company’s stock worth $427,000 after purchasing an additional 2,025 shares during the last quarter. Institutional investors own 95.10% of the company’s stock.
RUBY stock traded up $0.49 during midday trading on Wednesday, reaching $19.95. The company had a trading volume of 12,266 shares, compared to its average volume of 963,172. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -9.36 and a beta of 2.54. The stock has a 50 day moving average price of $22.18 and a 200-day moving average price of $23.27. Rubius Therapeutics has a 1-year low of $4.20 and a 1-year high of $38.71. The company has a debt-to-equity ratio of 0.29, a current ratio of 12.12 and a quick ratio of 12.12.
About Rubius Therapeutics
Rubius Therapeutics, Inc engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Cambridge, MA.
See Also: When is a capital gain realized?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.